Meet Dr. Mirko Manchia: A Pioneer in Bipolar Precision Care

In a comprehensive Genomic Press Interview published today in Genomic Psychiatry, Dr. Mirko Manchia discusses his journey from a small Sardinian city to becoming a leading voice in psychiatric pharmacogenomics. He shares how personal family experiences with mental illness inspired his quest to understand why psychiatric medications work differently for patients.

Dr. Manchia, an Associate Professor of Psychiatry at the University of Cagliari, has focused on the effectiveness of lithium in bipolar patients. His research led to identifying genetic markers for lithium response, aiming to predict treatment outcomes early on.

As a co-investigator of the International Consortium on Lithium Genetics (ConLiGen), Dr. Manchia has contributed to significant pharmacogenetic efforts. His work bridges laboratory discoveries with patient care, emphasizing the importance of precision medicine in psychiatry.

Dr. Manchia envisions a future where genetic testing becomes routine in psychiatric care, aiming to minimize trial-and-error medication adjustments. He advocates for increased research funding in psychiatry and emphasizes the need for patient-centered approaches.

Looking ahead, Dr. Manchia sees a future where digital monitoring, genomics, and brain imaging converge to transform mental health management. Despite technological advancements, he remains grounded in his passions for Roman history, classical music, and playing guitar.

The Genomic Press Interview with Dr. Mirko Manchia provides insights into his research and personal reflections, showcasing the blend of professional achievements and human themes that shape his work.

According to the source: Mirage News.